Cowen to host conference call to discuss third quarter financial results on Friday, October 29. Click here for more information.

$257.025 Million

Kymera Therapeutics

Follow-on Offering

Bookrunner, June 2021

Kymera Therapeutics, Inc. (the “Company” or “Kymera”) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s Pegasus platform enables the discovery of highly selective small molecule protein degraders with activity against disease causing proteins throughout the body. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

More Like This

Jul 2021
$584.78 Million

Follow-on Offering

Bookrunner

View Details
Jul 2021
$115.23 Million

Follow-on Offering

Lead Left Bookrunner

View Details
May 2021
$388.13 Million
R1 logo

Follow-on Offering

Co-Manager

View Details